^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
maplirpacept (TTI-622)
i
Other names: TTI-622, PF-07901801, TTI622, TTI 622, SIRPa-IgG4-Fc, PF 07901801, PF07901801
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Pfizer
Drug class:
CD47 inhibitor
Related drugs:
1m
A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma (clinicaltrials.gov)
P1, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
Trial completion date • Trial primary completion date
|
Darzalex Faspro (daratumumab and hyaluronidase-fihj) • maplirpacept (TTI-622)
1m
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors. (PubMed, J Hematol Oncol)
HCB101 demonstrates high-affinity binding to CD47, robustly promotes macrophage-mediated phagocytosis of tumor cells without affecting red blood cells and exhibits unique advantages over current CD47-targeting agents, including Hu5F9-G4, TTI-622, and ALX148. Additionally, HCB101 treatment increased the M1/M2 macrophage ratio in the tumor microenvironment, suggesting repolarization of tumor-associated macrophages (TAMs) toward a pro-inflammatory phenotype. No dose-limiting toxicities or hematologic adverse effects were observed in murine or non-human primate studies.
Preclinical • Journal • IO biomarker
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
magrolimab (ONO-7913) • evorpacept (ALX148) • HCB101 • maplirpacept (TTI-622)
2ms
C4971006: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. (clinicaltrials.gov)
P1/2, N=24, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=70 --> 24 | Trial completion date: Sep 2028 --> Mar 2026 | Trial primary completion date: Sep 2026 --> Mar 2026
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
3ms
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P1/2, N=6, Terminated, Pfizer | Phase classification: P2 --> P1/2
Phase classification
|
lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
3ms
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
P2, N=10, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=41 --> 10 | Trial completion date: Nov 2027 --> Jul 2027 | Trial primary completion date: Nov 2026 --> Jul 2027
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
|
ALK positive
|
Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)
5ms
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=6, Terminated, Pfizer | Phase classification: P1/2 --> P2 | Active, not recruiting --> Terminated; The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns
Phase classification • Trial termination
|
lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
9ms
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. (PubMed, Front Immunol)
Moreover, phagocytosis of neoplastic cells can be enhanced when maplirpacept is combined with other therapeutic agents, including antibodies or chemotherapeutic agents. These preclinical results establish maplirpacept as an effective CD47 blocker that mitigates the potential for anemia in patients.
Journal
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
maplirpacept (TTI-622)
10ms
MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=90, Recruiting, Pfizer | Trial completion date: Nov 2027 --> Feb 2028 | Trial primary completion date: Dec 2025 --> Apr 2026
Trial completion date • Trial primary completion date
|
carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
1year
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China (clinicaltrials.gov)
P1, N=10, Completed, Pfizer | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Nov 2024
Trial completion • Trial completion date • Metastases
|
maplirpacept (TTI-622)
1year
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
P1/2, N=10, Terminated, Pfizer | Phase classification: P2 --> P1/2
Phase classification • Combination therapy
|
pegylated liposomal doxorubicin • maplirpacept (TTI-622)
1year
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies (clinicaltrials.gov)
P1, N=7, Completed, Pfizer | Active, not recruiting --> Completed
Trial completion
|
maplirpacept (TTI-622)
1year
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
P2, N=10, Terminated, Pfizer | Phase classification: P1/2 --> P2
Phase classification • Combination therapy
|
pegylated liposomal doxorubicin • maplirpacept (TTI-622)
Share via
